

ORASURE TECHNOLOGIES INC

Form 8-K

May 18, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 16, 2006

OraSure Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-16537
(Commission File Number)

36-4370966
(I.R.S. Employer
Identification No.)

220 East First Street
Bethlehem, Pennsylvania
(Address of Principal Executive Offices)

18015-1360
(Zip Code)

Registrant's telephone number, including area code: 610-882-1820

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

- “ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01 Entry into a Material Definitive Agreement.

On May 16, 2006, OraSure Technologies, Inc. (the "Company") held its 2006 Annual Meeting of Stockholders. At the meeting, the Company's stockholders approved the amendment and restatement of the Company's 2000 Stock Award Plan (the "Plan"). Pursuant to the Plan, the Company's employees and non-employee members of the Company's Board of Directors are eligible to receive grants of stock options and other equity awards. A copy of the Plan as amended and restated is attached to this Report as Exhibit 10 and is incorporated by reference herein.

Item 7.01 Regulation FD Disclosure.

On May 18, 2006, the Company issued a press release announcing that the Centers for Disease Control and Prevention ("CDC") had provided the Company with a \$2.3 million bulk purchase order for its OraQuick® ADVANCE Rapid HIV-1/2 Antibody Test. The press release also included an update of the Company's 2006 financial guidance to incorporate the expected impact of this new order. A copy of the press release is attached as Exhibit 99 to this Report and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
10	OraSure Technologies, Inc. 2000 Stock Award Plan, as amended and restated effective May 16, 2006.
99	Press Release, dated May 18, 2006, announcing a new bulk purchase of OraQuick® ADVANCE Rapid HIV-1/2 Antibody Tests by the Centers for Disease Control and Prevention.

Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ORASURE TECHNOLOGIES, INC.

Date: May 18, 2006

By: */s/ Jack E. Jerrett*
Jack E. Jerrett
Senior Vice President, General Counsel and Secretary

Index to Exhibits

Exhibit No.	Description
10	OraSure Technologies, Inc. 2000 Stock Award Plan, as amended and restated effective May 16, 2006.
99	Press Release, dated May 18, 2006, announcing a new bulk purchase of OraQuick® <i>ADVANCE</i> Rapid HIV-1/2 Antibody Tests by the Centers for Disease Control and Prevention.